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Introduction
The use of antithrombotic medication following transcatheter aortic valve replacement (TAVR) is currently based on empirical data and mainly derived from clinical experience with coronary stenting and established surgical valve procedures. The risk of thromboembolic events after TAVR have been reported to be the highest within the first days after intervention, in line with the experience gained over the last decades from surgical bioprosthetic valves [1] [2] [3] . Current multisociety guidelines recommend a dual antiplatelet regimen defined as a combination of low-dose aspirin and the thienopyridine clopidogrel for at least 3 to 6 months after TAVR [4] . However, data supporting this concept are sparse. A recently published propensity matched analysis of pooled data from 672 TAVR patients treated with either dual antiplatelet therapy (DAPT) or aspirin alone suggests that DAPT is associated with higher rates of bleeding complications compared to aspirin monotherapy, while net adverse ischemic and thrombotic events, including stroke, did not differ between the groups at 30 days [5] . Patients undergoing TAVR with underlying atrial fibrillation (AF) or previous thromboembolic events constitute a particularly challenging population with regard to the post-interventional antithrombotic management. AF has been reported in more than 30% of the patients considered for TAVR and is associated with a markedly increased risk of mortality and thromboembolic events after valve replacement [6, 7] . In addition, new onset AF was observed in one third of the patients undergoing continuous electrocardiographic (ECG)-monitoring after TAVR and associated with higher rates of postprocedural embolic events [8] . Identifying the appropriate anticoagulation strategy after TAVR remains an important clinical challenge that has resulted in a large variability of antithrombotic therapies, ranging from triple therapy (DAPT + oral anticoagulation [OAC] ) to vitamin-K antagonists (VKA) alone [9] . Finally, recent reports on low but clinically relevant incidence of valve thrombosis hindering prosthesis function may further lead to an upheaval in the landscape of thrombotic therapy after TAVR [10] [11] [12] .
The objective of the present retrospective single center registry analysis was to compare the safety and efficacy outcomes for up to 1 year of either an antiplatelet therapy or OAC after TAVR.
Methods

Study design
This retrospective analysis was performed in a single-center prospective cohort study aiming for consecutive enrolment of all patients undergoing TAVR procedures at the Heart Center Segeberger Kliniken, Bad Segeberg, Germany. Data collection was approved by the local ethics committee and informed written consent was obtained from all patients. The current analysis includes 514 consecutive patients who underwent TAVR between September 2007 and December 2014 at the Heart Center Segeberger Kliniken, Germany. Twenty patients were excluded from this analysis because of antithrombotic treatments other than DAPT or OAC, or due to procedure related death (Fig. 1) .
Procedure
Transcatheter aortic valve replacement was performed in all patients with Conformité Européenne marked devices. TAVR procedures were conducted via trans-femoral, trans-subclavian, trans-apical or trans-aortic access sites. Device success was defined according to the Valve Academic Research Consortium 2 (VARC-2) consensus document, which is a technical composite end point including successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system; correct position of the device in the proper anatomical location; intended performance of the prosthetic heart valve (aortic valve area [AVA] > 1.2 cm without moderate or severe prosthetic valve aortic regurgitation as assessed by post-interventional transthoracic echocardiography [TTE] ) and having only 1 valve implanted in the proper anatomical location [13, 14] .
Antithrombotic regimen following TAVR
Patients were categorized into two groups based on the antithrombotic therapy established after TAVR. The DAPT group consisted of 315 (61.3%) patients treated with a combination of oral aspirin and clopidogrel for 3 months followed by lifelong aspirin therapy. The OAC group included 199 (38.7%) patients treated with a combination of an OAC + clopidogrel for 3 months followed by OAC alone (Fig. 1) . In patients treated with concomitant percutaneous coronary intervention (PCI) and drug-eluting stent implantation antithrombotic therapy with DAPT or combination of OAC + clopidogrel was pursued for up to 6 months.
Follow-up and study endpoints
All patients in the registry had a pre-defined clinical and transthoracic echocardiographic (Vivid 7 Ultrasound Machine and a M4S matrix array sector transducer GE Medical Systems, Milwaukee, WI, USA) follow-up at 30 days, 6 months and 1 year. Additional transesophageal echocardiography (TEE) evaluation was performed in cases of worsening symptoms or suspected valve thrombosis, defined as valve dysfunction (mean transvalvular gradient > 20 mm Hg, reduction of the AVA to < 1.2 cm 2 or new onset more than mild transvalvular regurgitation) or newly apparent mobile mass suspicious of thrombus, irrespective of dysfunction, and in the absence of infection. In addition, multidetector computed tomography (MDCT) examination was performed to further confirm the diagnosis of suspected valve thrombosis. CT examination was done with a second generation dual-source CT scanner (Somatom Definition Flash, Siemens Healthcare, Forchheim, Germany). Contrast enhanced ECG-gated acquisition of the aortic root was performed after injection of iodinated contrast agent with the region of interest placed in the ascending aorta and axial sections of 0.6 mm. All data were transferred to a dedicated post-processing workstation (Syngo Multimodality Workplace, Siemens Healthcare, Forchheim, Germany) for analysis. Images were evaluated for hypoattenuating areas with or without reduced mobility of one or more leaflets identifiable in two different projections. Valve thrombosis was classified based on the timing of diagnosis after TAVR as acute (0-10 days); subacute (11-30 days) or late (> 1 month). Pre-specified efficacy endpoints of this study were defined as all-cause death, myocardial infarction (MI), stroke and clinical valve thrombosis at 30 days, 6 months and 1 year. The key efficacy endpoint was a composite of all at 1 year. The key safety endpoint was the occurrence of life threatening or major bleeding at 1 year. Individual endpoints were defined according to the VARC-2 criteria for event definition [14] .
Statistical analysis
Continuous data are reported as mean ± standard deviation (SD) for normally distributed variables and as median with interquartile range (IQR) for non-normally distributed variables. Categorical variables are reported as number of patients (% of patients). Normally and nonnormally distributed variables were compared using the Student's t-test or the Mann-Whitney U test accordingly. Comparisons between categorical variables were performed using the c 2 or Fisher's exact test, wherever appropriate. In order to identify whether the anti-thrombotic treatment strategy was predictive of all-cause mortality, cardiovascular mortality, stroke, major bleeding, or combined efficacy and safety endpoints multivariable binary logistic regression analysis was performed. Variables which reached a p-value < 0.1 on univariate binary regression analysis were included in the model. Variables are adjusted for age, sex, body mass index (BMI), AF and staged PCI. All tests were two-tailed and a p-value of < 0.05 was considered as statistically significant. All the analyses were retrospective and performed using STATA version 14 (STATA Corp., TX, USA) or SPSS (SPSS, Release 22; SPSS Inc, Chicago, IL).
Results
A total of 514 consecutive patients that underwent TAVR at the indicated institution were included in this study. The mean age of the study population was 80.4 years, 43.7% were males, with a median logistic EuroScore of 18.49%. In both groups patients had severe aortic stenosis. Echocardiographic characteristics did not differ significantly in either group. The mean (± SD) gradient was 46 ± 16. (Table 1 ), except for a higher incidence of AF in the OAC group (10.5% vs. 69.2%; p < 0.01) and a higher rate of staged PCI in patients undergoing TAVR in the DAPT group (40.1% vs. 28.3%; p = 0.01). Procedural characteristics did not differ between either group (Table 2) . At discharge, 315 (61.3%) patients received DAPT and 199 (38.7%) a combination of OAC and clopidogrel (n = 188 phenoprocoumon, n = 7 rivaroxaban, n = 4 dabigatran) following TAVR ( Fig. 1 ).
Outcomes at 30 days
At 30 days, all-cause mortality occurred in a total of 18 (3.5%) patients, 11 (3.5%) in the DAPT group and 7 (3.5%) in the OAC group (p = 0.98) ( Table 3) . Cardiovascular mortality was reported in Outcomes at 6 months At 6 months, all-cause mortality was reported in 25 (7.9%) patients in the DAPT group and 24 (12.1%) patients in the OAC group (p = 0.15) ( Table 4 ). There was no significant difference between DAPT and OAC groups in the incidence of MI (1.6% vs. 0.5%, p = 0.41) and stroke (4.5% vs. 4.1%, p = 0.83). Although valve thrombosis was only reported in the DAPT group, there was no statistically significant difference (1.9% vs. 0%, p = 0.08) between the groups after 6 months. Combined efficacy (15.3% vs. 14.6%, p = 0.8) and safety (24.4% vs. 26.1%, p = 0.64) endpoints at 6 months did not differ significantly (Table 4) .
Safety and efficacy endpoints at 1 year
At 1 year all-cause mortality had occurred in a total of 74 (14.4%) patients. 39 (12.4%) deaths were reported in the DAPT group and 35 (17.6 %) in the OAC group (Fig. 2) . Even though a trend towards a higher mortality rate could be observed in the OAC group, this increase did not reach statistical significance (p = 0.09). Furthermore, there was no difference in MI (2.9% vs. 0.5%, p = 0.09) and stroke (5.2% vs. 4.1%, p = 0.67) rates between the DAPT and OAC groups. After 1 year, 8 (2.5%) cases of valve thrombosis were documented in the group of patients on antiplatelet treatment, while in patients on OAC no valve thrombosis was reported (2.5% vs. 0%, p = 0.02). Combined key efficacy (21.5% vs. 19.7%, p = 0.61) and safety (25.1% vs. 27.8%, p = 0.53) endpoints at 1 year did not differ between the groups (Fig. 3 ). An adjusted logistic regression analysis confirmed that despite a trend towards an increase in all-cause mortality after 1 year observed in patients under OAC there was no overall statistically significant difference in the occurrence rates of the predefined endpoints (Fig. 3) . However, OAC reduced the risk of valve thrombosis independent of age, sex, BMI, AF and whether staged PCI was performed (OR 0.53; 95% CI 0.23-0.76).
Clinical features of transcatheter heart valve thrombosis
In the current analysis transcatheter heart valve (THV) thrombosis was reported in 8 patients with a mean age of 78.7 years. Median and mean time to diagnosis of THV thrombosis were 181 (IQR 176-263) days and 196 days, respectively. THV thrombosis was considered to be subacute in 1 and late in 7 patients (Table 5 ). All 8 cases of THV thrombosis occurred in the DAPT group. While 2 patients were still under DAPT (aspirin/ /clopidogrel) 6 patients were under aspirin monotherapy at the point in time of diagnosis of THV thrombosis. Cases of valve thrombosis included 7 patients who had undergone TAVR with a balloon expandable THV and 1 patient treated with a selfexpandable THV. Three cases of THV thrombosis or peripheral embolism could be associated to THV thrombosis. Elevated transvalvular gradients was the leading finding in all patients on TTE examination. The peak and mean transaortic gradients at the time of diagnosis of THV thrombosis were 61 mm Hg and 39 mm Hg, respectively. TEE was performed in all patients with suspected THV thrombosis. TEE findings included restricted leaflet mobility (n = 3), thrombotic mass (n = 3) and thickened leaflets (n = 4) ( Table 5 ). In 1 case TEE was inconclusive. CT examination was performed in 4 patients and demonstrated hypoattenuated lesions of the leaflets and restricted leaflet motion consistent with THV thrombosis. All patients diagnosed with THV thrombosis were treated with VKA in therapeutic doses. Three patients were treated in addition with clopidogrel. Under OAC follow-up TTE examinations documented a decrease of the transvalvular gradients in all patients. Follow up CT was performed in 3 patients 1 (n = 2) and 2 (n = 1) months after initiation of anticoagulant therapy confirmed resolution of the hypoattenuated lesions and leaflet thickening with restoration of leaflet motion. After resolution of THV thrombosis OAC was ceased in 3 patients while VKA treatment was continued in 5 patients. No recurrence of THV thrombosis was reported.
Modification of therapeutic regimen
During the observational period of 1 year, 37 patients underwent modification of their therapeutic regimen. 19 patients of the DAPT group switched to OAC and 18 patients of the OAC group switched to DAPT due to clinical indications. Follow-up classification and statistical analysis was based on an intention-to-treat analysis.
Discussion
This retrospective analysis of a single center registry compared outcomes of two antithrombotic regimen following TAVR. After a follow-up period of 1 year no significant differences in predefined cumulative efficacy and safety endpoints were observed between an antithrombotic strategy based on early phase DAPT for 3-6 months according to current guideline recommendations and OAC.
However, clinical valve thrombosis after TAVR occurred only in the DAPT group and was successfully treated by the establishment of OAC.
Most cardioembolic events after TAVR were reported to occur within the first days after TAVR [15] . In the present study, the incidence of all-cause mortality, stroke and MI at 30 days was comparable to results previously published in prospective landmark trials as well as nationwide registries [16] [17] [18] [19] [20] . Post interventional DAPT or OAC resulted in similar rates of MI, stroke and all-cause mortality up to 6 months after TAVR thereby underscoring the efficacy of both therapeutic regimens. After 6 months, patients in the DAPT group were placed on single antiplatelet therapy (aspirin) while anticoagulation was pursued in the OAC group due to comorbidities, in particular paroxysmal or permanent AF. One year after TAVR, aspirin monotherapy also yielded similar results as compared to OAC regarding predefined efficacy endpoints. Hence, the present results are in line with previous studies strongly supporting an interruption of DAPT after a period of 3-6 months in TAVR patients who do not have any further indication for DAPT such as recent acute coronary syndrome (< 12 months) or coronary stent implantation (< 6 months) [5, 21, 22] . Interestingly, after 1 year, and despite adjustment for the occurrence of AF and other variables, a trend towards an increased all-cause mortality in the OAC group could be observed. Considering the limited size of the study population as well as the retrospective nature of the study, this observation requires careful interpretation.
In the relatively young era of percutaneous aortic valve replacement, an increasing number of reports has emerged describing cases of clinically relevant subacute post-TAVR valve thrombosis and recently identified reduced leaflet motion in MDCT, which may correspond to a subclinical surrogate of valve thrombosis [10, 11, [23] [24] [25] . These reports about post-TAVR valve thrombosis and hindered leaflet function have generated debate about the clinical relevance of this phenomenon. In the present study, valve thrombosis was diagnosed based on routine echocardiographic follow-up examination in 1.5% of the total population and as often as 2.5% in patients initially treated with DAPT. Diagnosis was based on echocardiographic parameters demonstrating a significant increase in transvalvular pressure gradients or thrombotic mass and confirmed by MDCT findings reporting thickening of the leaflets and reduced leaflet motion. THV thrombosis manifested as worsening of dyspnoea in 5 of 8 patients while it was not as-sociated to any clinical symptoms in 3 patients. In patients diagnosed with THV thrombosis, DAPT was replaced by OAC for at least 3 months and follow-up intervals were shortened. Follow-up echocardiography as well as clinical examination documented restoration of valve function under OAC by decreases of peak and mean transvalvular gradients over valve prosthesis, resolution of thrombotic mass as well as improvement of clinical symptoms in all patients. Interestingly, in contrast to the DAPT group, no cases of valve thrombosis were diagnosed in any of the patients on OAC and logistic regression analysis demonstrated that OAC was associated with a significantly lower risk of developing THV thrombosis. This observation is in line with current reports in the literature suggesting that OAC but not antiplatelet therapy prevents valve thrombosis [26] [27] [28] . Further studies are required in order to better characterize this subgroup of patients and to identify potential predictors which reveal those patients who may benefit from OAC after TAVR apart from other indications for anticoagulant therapy.
Hemorrhagic complications are frequent, and major or life-threatening bleeding after TAVR occur in 20-30% and 15%, respectively [16, 17, 29] . Regardless of the underlying mechanisms, disabling or life-threatening bleeding is an important predictor of acute and late mortality in patients undergoing TAVR. Predictors of bleeding complications have been identified by several groups [30, 31] . Among them, vascular or major intraprocedural complications, female sex, and baseline anemia have been most frequently reported. While periprocedural bleeding is driven mainly by anatomical and technical considerations, major and life-threatening bleeding occurring at later points in time appear to be related mainly to patient bleeding susceptibility, triggered by the antithrombotic agent used. In the current analysis the composite safety endpoint occurred mainly within the first 6 months after TAVR in both groups. This observation strongly suggests that both DAPT and the combination of OAC with a single antiplatelet drug such as clopidogrel results in a significant increase of hemorrhagic complications after TAVR in a patient population that is at particular high risk for bleeding due to comorbidities and frailty. At 1 year the incidence of the composite safety endpoint was only slightly higher in both groups as compared to the 6 months time point and was mostly related to the fact that after a maximum of 6 months thienopyridine therapy was ceased in patients without an indication for further long-term clopidogrel treatment such as acute coronary syndrome. Previous studies and registries have reported a short-term hazard related to bleeding complications that were most apparent during the first 3 months of initiation of either VKA plus a single antiplatelet drug or DAPT treatment [32, 33] . A most recent meta-analysis excluding patients on OAC demonstrated that aspirin monotherapy while being as efficient as DAPT in preventing post-interventional thromboembolic complications and was superior to DAPT with regard to bleeding complications [5] . Taken together these observations may challenge the current practice recommending DAPT for 3-6 months after TAVR but these results need to be confirmed by currently ongoing prospective randomized trials. With regard to the management of antithrombotic therapy after TAVR in patients on OAC, further data reporting is warranted. In this retrospective analysis patients on OAC were treated with clopidogrel for at least 3 months after TAVR according to current recommendations [4] . Since the majority of the bleeding events occurred in this group within the first 6 months, the net benefit of adding a platelet inhibitor on top of OAC may be questioned. As for DAPT, prospective randomized trials are required to define the most appropriate antithrombotic post-TAVR therapy in patients on OAC. Finally, while the newer direct oral anticoagulants have proven to be safer and at least as efficient as VKA in the prevention of thromboembolic events in patients with underlying non-valvular AF, their role in patients undergoing TAVR remains to be defined.
Limitations of the study
As for every retrospective cohort analysis limitations such as patient and treatment selection biases need to be considered. The reporting in this study followed the VARC-2 criteria and was predefined. TEE and MDCT examinations were only performed in patients with suspected valve thrombosis defined by worsening transvalvular gradient on follow-up TTE or new onset of symptoms. Hence, it seems likely that the incidence of subclinical valve thrombosis which may be more accurately diagnosed by routine MDCT or TEE examination may have been underestimated in this retrospective study.
Conclusions
This single center analysis suggests that DAPT and OAC are associated with similar clinical outcomes at 1 year with regard to predefined www.cardiologyjournal.org safety and efficacy endpoints in patients undergoing TAVR. In addition, OAC seems to reduce the risk of clinical valve thrombosis without a significant increase in major bleeding complications. Further randomized controlled trials assessing the optimal antithrombotic therapy after TAVR are both justified and needed.
